---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-24-000065"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2024-12-18T23:59:59+00:00"
generated_at: "2026-05-29T02:02:15.235721+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech reports 27% ORR and 73% DCR for inhaled KB707 in advanced NSCLC

## Summary
- ORR of 27% (3 partial responses) and DCR of 73% in 11 evaluable NSCLC patients as of Dec 6, 2024.
- Lung target lesion ORR 36% (3 partial, 1 complete response) and DCR 82%.
- Treatment-emergent AEs mild to moderate; no Grade 4/5 events; outpatient administration feasible.
- Protocol amended to add two combination cohorts (with anti-PD-1 ± chemo) for advanced NSCLC.
- Enrollment ongoing; detailed results to be presented at future scientific meetings.

## SEC filing metadata
- accession: 0001711279-24-000065
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2024-12-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127924000065/0001711279-24-000065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127924000065/krys-20241218.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-24-000065
- JSON: https://secwatch.observer/filing/0001711279-24-000065.json
- Plain text: https://secwatch.observer/filing/0001711279-24-000065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.